In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia
(2009) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 33(1). p.46-53- Abstract
- Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1313732
- author
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Doxorubicin, Prednisolone, 21), t(12, MRD, In vitro drug resistance, Acute lymphoblastic leukemia, Childhood
- in
- Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
- volume
- 33
- issue
- 1
- pages
- 46 - 53
- publisher
- Elsevier
- external identifiers
-
- wos:000261680400007
- scopus:55049113568
- ISSN
- 1873-5835
- DOI
- 10.1016/j.leukres.2008.06.012
- language
- English
- LU publication?
- yes
- id
- 4799634c-3027-4b5e-bdbf-6d9e16f4142f (old id 1313732)
- date added to LUP
- 2016-04-01 11:42:35
- date last changed
- 2024-10-08 06:53:56
@article{4799634c-3027-4b5e-bdbf-6d9e16f4142f, abstract = {{Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.}}, author = {{Lonnerholm, Gudmar and Thorn, Ingrid and Sundstrom, Christer and Frost, Britt-Marie and Abrahamsson, Jonas and Behrendtz, Mikael and Heldrup, Jesper and Jacobsson, Stefan and Li, AiHong and Olofsson, Tor and Porwit, Anna and Soderhall, Stefan and Larsson, Rolf and Forestier, Erik}}, issn = {{1873-5835}}, keywords = {{Doxorubicin; Prednisolone; 21); t(12; MRD; In vitro drug resistance; Acute lymphoblastic leukemia; Childhood}}, language = {{eng}}, number = {{1}}, pages = {{46--53}}, publisher = {{Elsevier}}, series = {{Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis}}, title = {{In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia}}, url = {{http://dx.doi.org/10.1016/j.leukres.2008.06.012}}, doi = {{10.1016/j.leukres.2008.06.012}}, volume = {{33}}, year = {{2009}}, }